ProMIS Neurosciences Inc

Research ProMIS Neurosciences Inc (PMN) on Bullrun: market cap USD 137.74M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 137.74M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 39.72M-USD 28.12Mn/a-22.61USD 6.12Mn/a-USD 1.26M
FY2024USD 0USD 2.78M-USD 27.18Mn/a2.63USD 13.29Mn/aUSD 16.49M
FY2023n/a-USD 13.21Mn/an/a-1.07USD 12.60MUSD 0USD 3.75M
FY2022n/a-USD 18.06M-USD 17.04Mn/a-2.41USD 5.88Mn/a-USD 1.35M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 137.74Mn/an/an/a
20252025-12-31USD 14.70Mn/an/an/a
20242024-12-31USD 31.06Mn/an/an/a
20232023-12-29USD 21.72Mn/an/an/a
20222022-12-30USD 37.24Mn/an/an/a
20212021-12-31USD 47.49Mn/an/an/a

About ProMIS Neurosciences Inc

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is ProMIS Neurosciences Inc's market cap?

ProMIS Neurosciences Inc's market capitalization is USD 137.74M.

What does ProMIS Neurosciences Inc do?

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.